Effect of Metformin on the esRAGE levels in type 2 diabetic patients: the Metformin Sitagliptin Randomized Trial - METS trial

Osaka City University Graduate School of Medicine, Metabolism, Endocrinology, and Molecular Medicine0 个研究点目标入组 60 人开始时间: 2011年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)The use of oral hypoglycemic agents, insulin preparations adrenocorticosteroid within 12 weeks prior to the start of observation period. 2)Patients with severe ketosis, diabetic coma, or with precoma 3)Patients with severe infections, before or after operation, or with serious trauma. 4)AST, ALT <=2.5 x Upper limit of facility reference at most recent of the registration, or patients with hepatic cirrhosis. 5)Patients with renal impairment.(Diabetic nephropathy staging >=stage3B before registration.) 6)Serve cardiovascular or pulmonary disorders, including shock, heart failure, myocardial infarction, lung infarction etc., or other conditions that are apt to cause hypoxemia. 7) Patients suffering from malnutrition, inanition, debility, pituitary gland malfunction, or adrenal gland dysfunction. 8)History of lactic acidosis. 9)Patients with a malignant tumor treated now. 10)History of hypersensitivity to biguanide oral hypoglycemic agent or DPP-4 inhibitor. 11)Pregnant women or women suspected of being pregnant. 12)Other patients determined to be inappropriate by physician.

发起方

Osaka City University Graduate School of Medicine, Metabolism, Endocrinology, and Molecular Medicine